Home

West Bound and Down

After fortuitously sheltering in place on the east coast for seven weeks, we are heading back for CA this week. We seem to have,...

Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous...

Tailwinds' Take: very positive results for CKPT, which is a partner company of Fortress Bio (FBIO). This is a potentially disruptive drug for a...

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Tailwinds' Take: Jiangsu is one of the two largest pharmaceutical companies in China. "This is a major shot across the bow of big pharma,"...

LexaGene’s Covid-19 Diagnostic Readies For The FDA

As we near the election, one thing that upon which both democrats and republicans seem to agree is that testing for Covid-19 has been...

Muscle Maker Grill Ghosting NYC With Two New Ghost Kitchens

Tailwinds' Take: GRIL continues to expand in the highly profitable category of Ghost Kitchens. With their differentiated, niche strategy and a recent financing, we...

INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support...

Tailwinds' Take: to quote CEO, RJ Tesi, "This award reinforces one of INmune Bio’s fundamental drug development tenets – by targeting the underlying biology,...

TFF Pharmaceuticals Announces Topline Results of Voriconazole Inhalation Powder Phase 1 Clinical Trial

Tailwinds' Take: very exciting news. TFF's inhaled version of Voriconazole, if approved, will be the first inhaled antifungal. This is the ideal medication for...

Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis

Tailwinds' Take: long-term survival data supports the thesis for CAEL-101 demonstrating efficacy in phase 3, which would most likely trigger the acquisition by Alexion....

Under The Radar…Key Data-Points From The Last Week That Nobody Really Noticed

The easiest way to make money in the market is trading off of insider information. It is also highly illegal, will put you in...

Muscle Maker Grill Announces Pricing of $5.6 Million Follow-On Public Offering to Fund Future...

Tailwinds' Take: great to get this financing over with. Now the Company is funded and able to execute their strategy with no overhang. Burleson, Texas,...

Avenue Therapeutics Announces Publication of a Review of IV Tramadol

Tailwinds' Take: more endorsement of a product whose PDUFA date (Oct. 10th) is rapidly approaching. We continue to believe IV Tramadol will get approval...

Ontrak Announces Full Exercise of Overallotment Option in Public Offering of Non-Convertible Preferred Stock

Tailwinds' Take: OnTrak is now fully funded and has the financial capability to grow their team to meet the demand of their clients.  Santa Monica,...

Illuminating Lantern Pharma

Today we are initiating coverage of Lantern Pharma (LTRN). Lantern is a clinical stage biopharmaceutical company that uses artificial intelligence, advanced machine learning, genomics,...

Hello Fall!

What a difference a week makes. Last Saturday I was writing about an epic (for Tailwinds) stretch of performance and salivating over all the...

INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering...

Tailwinds' Take: good news as INmune's INKmune program, which has shown great early stage data, is now protected. INMB continues to execute on two...

Is It Finally Time For Anixa to Shine?

A little more than a year and a half ago, I declared that Anixa (ANIX) was my stock of the year for 2019. They...

What’s Next for TFF?

TFF Pharma (Nasdaq: TFFP) had a big summer. First came the news about an internal program that appears to successfully reformulate Gilead’s Remdesivir into...

Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe...

Tailwinds' Take: MBIO continues to execute on the regulatory pathway for their drugs. We continue to believe the stock is significantly undervalued. WORCESTER, Mass., Sept....

INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor™ in a...

Tailwinds' Take: great news as we believe Quellor has a great opportunity to not only have a positive impact in Covid-19 but also the...

Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked...

Tailwinds' Take: the MBIO platform is greatly undervalued in our opinion. This gives them a second program with a rare pediatric disease designation. And,...

Become a Tailwinds Member

All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.

For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $250 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.

SIGN ME UP

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.